Reporting from ESMO Congress 2023 in Madrid, Marina Garassino discusses the results from two important studies on combination treatments in first-line oncogene addicted advanced NSCLC.
Abstracts discussed:
- LBA68 - FLAURA2: safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC, presented by David Planchard
- LBA65 - KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation, presented by Marina Garassino